Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).
This is one of six trials of lirilumab that is being sponsored by Bristol-Myers Squibb.
Pierre Dodion, Chief Medical Officer of Innate Pharma, said: “Although we knew that this setting was challenging, we are disappointed by the results of the EffiKIR study and will investigate further to better understand the data in its entirety. However, Effikir is only one of seven studies currently investigating lirilumab. Lirilumab is tested in a broad and comprehensive combination program in multiple indications and we saw encouraging early efficacy signals of lirilumab in combination with nivolumab at the 2016 SITC meeting. We are looking forward to the next data sets as well as the next steps for the program in 2017.”